While most endometrial cancers are caught early and treated successfully with surgery, a subset of patients develops recurrent or platinum-resistant disease -- cancer that no longer responds to standard chemotherapy regimens based on carboplatin and paclitaxel. These patients have limited treatment options and poor prognoses.
Drug screening -- testing many therapeutic candidates against cancer cells to find effective treatments -- is a critical step in identifying new drugs for resistant disease. However, conventional 2D cell culture systems grown in flat plastic dishes poorly recapitulate the three-dimensional structure and behavior of tumors in the body, limiting the predictive value of drug screen results.
Cancer organoids are miniature, three-dimensional tumor models grown from patient-derived cancer cells that maintain the architectural complexity and molecular heterogeneity of the original tumor. They are increasingly used as more accurate platforms for drug screening and personalized medicine testing.
Growing organoids requires a biocompatible scaffold -- a three-dimensional matrix that supports cell survival, growth, and organization. Matrigel, the most common scaffold, is derived from mouse tumor cells and has batch-to-batch variability, making it unsuitable for clinical translation.
The researchers designed a synthetic peptide scaffold using the RFC peptide -- a short amino acid sequence with self-assembly properties. To understand and optimize the scaffold's structure, they used AlphaFold3, the latest version of DeepMind's protein structure prediction system, to computationally predict the three-dimensional conformation of the RFC peptide.
AlphaFold3 predicted that the RFC peptide forms an alpha-helical structure, which is favorable for hydrogel self-assembly. Alpha helices stack and interact in predictable ways that can drive the formation of fibrous networks -- the physical basis of hydrogel scaffolds. This structural prediction guided the experimental design and formulation of the RFC hydrogel.
Endometrial cancer cells were embedded in the self-assembling RFC hydrogel and cultured under three-dimensional conditions. The hydrogel polymerized around the cells, providing mechanical support while allowing nutrient diffusion and cell-cell interactions that mimic the tumor microenvironment.
Organoid formation was assessed by microscopy over several days. Cells successfully formed compact spheroidal structures within the RFC hydrogel, demonstrating that the scaffold supports three-dimensional growth. The organoids maintained viability and proliferation rates comparable to those in Matrigel.
The RFC hydrogel was fully synthetic, reproducibly manufacturable, and composed of defined chemical components -- overcoming the batch variability limitation of Matrigel. This reproducibility is essential for drug screening applications where consistent scaffold properties are needed to reliably compare drug effects across experiments.
Using organoids grown in RFC hydrogel, the researchers screened a panel of clinically relevant chemotherapy agents against platinum-resistant endometrial cancer cells. The tested drugs included carboplatin, paclitaxel, doxorubicin, and several targeted agents.
Doxorubicin emerged as the most effective drug against platinum-resistant organoids, demonstrating significant cell killing at clinically achievable concentrations where other agents -- including the standard-of-care carboplatin -- were largely ineffective. This is consistent with doxorubicin's known activity in some endometrial cancer lines but confirms it in a more clinically relevant 3D model.
The drug response profiles differed substantially between organoids and conventional 2D cell cultures tested in parallel, validating the practical importance of the 3D model: drugs that appeared ineffective in 2D showed activity in 3D organoids, and vice versa, highlighting that culture geometry affects drug sensitivity measurements.
The ability to grow patient-derived organoids in a reproducible synthetic scaffold and perform drug screening directly on a patient's own tumor cells points toward personalized treatment selection. A patient with platinum-resistant recurrence could have her tumor cells grown as organoids and screened against available drugs before starting a new treatment course.
Doxorubicin is already approved for endometrial cancer and used in clinical practice, making the screening result immediately actionable. Identifying doxorubicin sensitivity in a patient's organoid before treatment begins could improve response rates by selecting patients most likely to benefit rather than treating empirically.
As organoid technology matures and culture costs decrease, rapid drug screening from biopsy within a clinically relevant timeframe (days to weeks) becomes increasingly feasible. The RFC scaffold's reproducibility is a critical enabler of this vision, as inconsistent scaffold batches would undermine the reliability of drug sensitivity comparisons.
This study demonstrates an end-to-end workflow connecting computational protein structure prediction (AlphaFold3) to organoid model development to clinically relevant drug screening. Each step builds directly on the previous, illustrating how AI tools can accelerate experimental cancer research.
The RFC hydrogel scaffold offers a defined, synthetic, scalable alternative to animal-derived matrices that could facilitate regulatory-grade organoid-based drug testing. Future work should expand the drug panel screened, validate findings in additional patient-derived endometrial cancer samples, and assess whether organoid drug sensitivity predicts clinical outcomes.
More broadly, the integration of AI structure prediction with synthetic biomaterials design represents a new paradigm for scaffold engineering -- one where computational prediction guides material chemistry rather than requiring exhaustive empirical iteration, potentially accelerating scaffold development for many tissue engineering and drug discovery applications.